Cargando…
NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease
Background: Inflammation and steatosis are the main pathological features of alcoholic liver disease (ALD), in which, inflammation is one of the critical drivers for the initiation and development of alcoholic steatosis. NIK, an inflammatory pathway component activated by inflammatory cytokines, was...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069072/ https://www.ncbi.nlm.nih.gov/pubmed/32206109 http://dx.doi.org/10.7150/thno.40149 |
_version_ | 1783505705689415680 |
---|---|
author | Li, Yaru Chen, Mingming Zhou, Yu Tang, Chuanfeng Zhang, Wen Zhong, Ying Chen, Yadong Zhou, Hong Sheng, Liang |
author_facet | Li, Yaru Chen, Mingming Zhou, Yu Tang, Chuanfeng Zhang, Wen Zhong, Ying Chen, Yadong Zhou, Hong Sheng, Liang |
author_sort | Li, Yaru |
collection | PubMed |
description | Background: Inflammation and steatosis are the main pathological features of alcoholic liver disease (ALD), in which, inflammation is one of the critical drivers for the initiation and development of alcoholic steatosis. NIK, an inflammatory pathway component activated by inflammatory cytokines, was suspected to link inflammation to hepatic steatosis during ALD. However, the underlying pathogenesis is not well-elucidated. Methods: Alcoholic steatosis was induced in mice by chronic-plus-binge ethanol feeding. Both the loss- and gain-of-function experiments by the hepatocyte-specific deletion, pharmacological inhibition and adenoviral transfection of NIK were utilized to elucidate the role of NIK in alcoholic steatosis. Rate of fatty acid oxidation was assessed in vivo and in vitro. PPARα agonists or antagonists of MEK1/2 and ERK1/2 were used to identify the NIK-induced regulation of PPARα, MEK1/2, and ERK1/2. The potential interactions between NIK, MEK1/2, ERK1/2 and PPARα and the phosphorylation of PPARα were clarified by immunoprecipitation, immunoblotting and far-western blotting analysis. Results: Hepatocyte-specific deletion of NIK protected mice from alcoholic steatosis by sustaining hepatic fatty acid oxidation. Moreover, overexpression of NIK contributed to hepatic lipid accumulation with disrupted fatty acid oxidation. The pathological effect of NIK in ALD may be attributed to the suppression of PPARα, the main controller of fatty acid oxidation in the liver, because PPARα agonists reversed NIK-mediated hepatic steatosis and malfunction of fatty acid oxidation. Mechanistically, NIK recruited MEK1/2 and ERK1/2 to form a complex that catalyzed the inhibitory phosphorylation of PPARα. Importantly, pharmacological intervention against NIK significantly attenuated alcoholic steatosis in ethanol-fed mice. Conclusions: NIK targeting PPARα via MEK1/2 and ERK1/2 disrupts hepatic fatty acid oxidation and exhibits high value in ALD therapy. |
format | Online Article Text |
id | pubmed-7069072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-70690722020-03-23 NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease Li, Yaru Chen, Mingming Zhou, Yu Tang, Chuanfeng Zhang, Wen Zhong, Ying Chen, Yadong Zhou, Hong Sheng, Liang Theranostics Research Paper Background: Inflammation and steatosis are the main pathological features of alcoholic liver disease (ALD), in which, inflammation is one of the critical drivers for the initiation and development of alcoholic steatosis. NIK, an inflammatory pathway component activated by inflammatory cytokines, was suspected to link inflammation to hepatic steatosis during ALD. However, the underlying pathogenesis is not well-elucidated. Methods: Alcoholic steatosis was induced in mice by chronic-plus-binge ethanol feeding. Both the loss- and gain-of-function experiments by the hepatocyte-specific deletion, pharmacological inhibition and adenoviral transfection of NIK were utilized to elucidate the role of NIK in alcoholic steatosis. Rate of fatty acid oxidation was assessed in vivo and in vitro. PPARα agonists or antagonists of MEK1/2 and ERK1/2 were used to identify the NIK-induced regulation of PPARα, MEK1/2, and ERK1/2. The potential interactions between NIK, MEK1/2, ERK1/2 and PPARα and the phosphorylation of PPARα were clarified by immunoprecipitation, immunoblotting and far-western blotting analysis. Results: Hepatocyte-specific deletion of NIK protected mice from alcoholic steatosis by sustaining hepatic fatty acid oxidation. Moreover, overexpression of NIK contributed to hepatic lipid accumulation with disrupted fatty acid oxidation. The pathological effect of NIK in ALD may be attributed to the suppression of PPARα, the main controller of fatty acid oxidation in the liver, because PPARα agonists reversed NIK-mediated hepatic steatosis and malfunction of fatty acid oxidation. Mechanistically, NIK recruited MEK1/2 and ERK1/2 to form a complex that catalyzed the inhibitory phosphorylation of PPARα. Importantly, pharmacological intervention against NIK significantly attenuated alcoholic steatosis in ethanol-fed mice. Conclusions: NIK targeting PPARα via MEK1/2 and ERK1/2 disrupts hepatic fatty acid oxidation and exhibits high value in ALD therapy. Ivyspring International Publisher 2020-02-18 /pmc/articles/PMC7069072/ /pubmed/32206109 http://dx.doi.org/10.7150/thno.40149 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Li, Yaru Chen, Mingming Zhou, Yu Tang, Chuanfeng Zhang, Wen Zhong, Ying Chen, Yadong Zhou, Hong Sheng, Liang NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease |
title | NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease |
title_full | NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease |
title_fullStr | NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease |
title_full_unstemmed | NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease |
title_short | NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease |
title_sort | nik links inflammation to hepatic steatosis by suppressing pparα in alcoholic liver disease |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069072/ https://www.ncbi.nlm.nih.gov/pubmed/32206109 http://dx.doi.org/10.7150/thno.40149 |
work_keys_str_mv | AT liyaru niklinksinflammationtohepaticsteatosisbysuppressingpparainalcoholicliverdisease AT chenmingming niklinksinflammationtohepaticsteatosisbysuppressingpparainalcoholicliverdisease AT zhouyu niklinksinflammationtohepaticsteatosisbysuppressingpparainalcoholicliverdisease AT tangchuanfeng niklinksinflammationtohepaticsteatosisbysuppressingpparainalcoholicliverdisease AT zhangwen niklinksinflammationtohepaticsteatosisbysuppressingpparainalcoholicliverdisease AT zhongying niklinksinflammationtohepaticsteatosisbysuppressingpparainalcoholicliverdisease AT chenyadong niklinksinflammationtohepaticsteatosisbysuppressingpparainalcoholicliverdisease AT zhouhong niklinksinflammationtohepaticsteatosisbysuppressingpparainalcoholicliverdisease AT shengliang niklinksinflammationtohepaticsteatosisbysuppressingpparainalcoholicliverdisease |